Monkeypox A29L protein, His Tag

Product Information
Primary Accession	Q77HM6
Species	Monkeypox
Sequence	Met1-Glu110
Purity	≥ 95% as analyzed by SDS-PAGE
Endotoxin Level	< 0.2 EU/ µg of protein by gel clotting method
Expression System	E.coli
Theoretical Molecular Weight	13.4 kDa
Formulation	Lyophilized from a 0.2 µm filtered solution in 2.5% D-(+)-Trehalose Anhydrous, 2.5% D-Mannitol, PBS, pH 7.4.
Reconstitution	Before opening, centrifuge the vial briefly to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml.
Storage & Stability	Upon receiving, the lyophilized product remains stable for up to 6 months at lower than -70 °C. Upon reconstitution, the product is stable for up to 1 week at 4 °C or up to 3 months at -20 °C. Avoid repeated freeze-thaw cycles by making single-use aliquots before the solution is storage at -20 °C.

Additional Information
Target Background	Monkeypox virus is an enveloped double-stranded DNA virus that belongs to the Orthopoxvirus genus of the Poxviridae family. It is a viral zoonosis that causes similar symptoms to smallpox, although it is clinically less severe. Vaccination against smallpox was demonstrated through several observational studies to be about 85% effective in preventing monkeypox. Since early May 2022, more than 16,000 cases of monkeypox have been reported from countries where the disease is not endemic, and continue to be reported in several endemic countries, WHO has claimed monkeypox as a "Public Health Emergency of International Concern (PHEIC)". The A29L protein from Monkeypox binds to cell surface heparin to promote fusion of viral membrane with host plasma membrane, it is a potential target for developing diagnosis and vaccine.